Shares of Hyperion Therapeutics soared nearly 20% today after receiving notice that the Food and Drug Administration would not meets its January PDUFA date for Ravicti. However, the reasons for the UCD drug's delay have the bulls out in full force. Watch as Motley Fool health care analyst David Williamson explains what has investors so excited and what it means for Hyperion.

What's inside Supernova?
If you're an investor looking for big long-term winners, Motley Fool co-founder David Gardner's picks have frequently trounced the market. How? Because he's always on the lookout for revolutionary stocks and recommends them before Wall Street catches on to their disruptive potential. If you're interested in how David discovers his winners, click here to get instant access to a personal tour behind David's Supernova service.


The article 1 Biotech Goes Hyper originally appeared on Fool.com.

David Williamson has no position in any stocks mentioned. Follow him on Twitter @MotleyDavid The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.


Increase your money and finance knowledge from home

Investing in Emerging Markets

Learn to invest in a globalized world.

View Course »

Introduction to Economic Indicators

Measure the performance of the economy.

View Course »

Add a Comment

*0 / 3000 Character Maximum